The FDA has approved triamcinolone acetonide ointment for the treatment of inflammatory and pruritic manifestations of dermatoses, Strides Pharma Science Limited announced in a press release.
Please provide your email address to receive an email when new articles are posted on . A 2.5 mg/mL dose of triamcinolone acetonide showed equally as efficacious treatment for nail psoriasis vs.
LAVAL, Quebec and ALPHARETTA, Ga., Oct. 23, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global ...
LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye ...
NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020 LAVAL, Quebec and ALPHARETTA, Ga., Oct. 23, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results